### Analysis

The Johnson & Johnson earnings call for the second quarter of 2012 revealed a mixed performance. The company reported a decrease in sales and earnings compared to the same period in 2011. The company's sales were down 0.7% compared to the second quarter of 2011, while earnings per share decreased from $1 to $0.50. The company's management attributed the decrease in sales to the impact of currency exchange rates and the divestiture of the DePuy trauma business to Biomet. The company also noted that the Synthes acquisition had a positive impact on its sales and earnings, but the divestiture of the trauma business had a negative impact. The company's management also highlighted the need for continued innovation and growth in its pharmaceutical and medical device businesses, as well as the need to expand its global reach.

### Conclusion

The short-term implications of the Johnson & Johnson earnings call for the second quarter of 2012 are likely to be negative. The company's sales and earnings decreased compared to the same period in 2011, and the company's management attributed the decrease to the impact of currency exchange rates and the divestiture of the DePuy trauma business to Biomet. The company's management also highlighted the need for continued innovation and growth in its pharmaceutical and medical device businesses, as well as the need to expand its global reach. The company's stock price is likely to face short-term pressure due to the decrease in sales and earnings, as well as the need for continued innovation and growth. However, the company's long-term prospects remain strong, as it continues to expand its global reach and invest in innovation in its pharmaceutical and medical device businesses.

### Rating

[-1]